Menu

Detecting New Synthetic Drugs

Forensic labs in the United States should be better equipped to identify a new crop of recreational drug mimics.

Sep 1, 2011
Cristina Luiggi

DREAMSTIME, HENRISCHMIT

Underequipped and inadequately staffed forensic laboratories around the United States are likely to miss the new class of synthetic drugs that are cropping up, mostly in China, said chemists at the American Chemical Society meeting in Denver, Colorado. The drugs, which are synthesized to mimic existing illegal substances while evading detection, represent a growing problem worldwide. Detecting them requires laboratories to have a pure sample for comparison using analytical techniques such as gas-column mass spectrometry (GCMS), but such samples are hard to come by. Another problem is that many forensic labs may be staffed by people without the proper training in analytical chemistry.

"If you're doing GCMS on a sample and it almost matches mephedrone, well maybe it's butylone [a psychedelic drug used in research]," said Robert Lantz from the Rocky Mountain Instrumental Laboratories at the meeting. "A good analytical chemist would be able to say 'yes, this is a slight variation' as opposed to a button pusher who would simply say 'it doesn't match anything in my library'." (Hat tip to Nature News)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.